Introduction
The Industrial Property Act 2014 of Uganda represents a key legislative framework for protecting intellectual property rights, particularly patents, within the country. Section 12(b) of the Act explicitly excludes from patentability inventions that are contrary to public order, morality, public health and safety, public policy, principles of humanity, and environmental conservation (Government of Uganda, 2014). This provision aligns with international standards, such as Article 27.2 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which Uganda, as a World Trade Organization (WTO) member, is obligated to uphold (World Trade Organization, 1994). However, this exemption raises important questions about its implications for the right to health, a fundamental human right implicitly recognised in Uganda’s 1995 Constitution under objectives like National Objective XX, which emphasises access to health services, and Article 8A, which promotes social and economic rights (Government of Uganda, 1995).
This essay examines how Section 12(b) impacts the right to health in Uganda, drawing on relevant case law to illustrate both protective and potentially restrictive effects. It argues that while the exemption safeguards public health by preventing patents on harmful inventions, it may also hinder innovation in health-related technologies if interpreted too broadly. The discussion is structured around an overview of the Act and the right to health, an analysis of the exemption, key case law, and the broader implications. By exploring these elements, the essay highlights the tension between intellectual property protections and health rights, informed by Uganda’s socio-economic context where access to affordable healthcare remains a challenge (World Health Organization, 2020).
Overview of the Industrial Property Act 2014 and Section 12(b)
The Industrial Property Act 2014, often cited as Cap 224 in some legal references, was enacted to modernise Uganda’s patent system, replacing outdated colonial-era laws and ensuring compliance with TRIPS (Government of Uganda, 2014). The Act aims to foster innovation by granting inventors exclusive rights, typically for 20 years, while balancing public interests. Section 12(b) is a critical safeguard, stating that patents shall not be granted for “inventions the prevention within Uganda of the commercial exploitation of which is necessary to protect public order or morality, including to protect human, animal or plant life or health or to avoid serious prejudice to the environment” (Government of Uganda, 2014, s.12(b)). This wording mirrors TRIPS Article 27.2, allowing member states to exclude inventions that could harm societal values or health.
In practice, this exemption prevents patenting of inventions deemed unethical or dangerous, such as those involving biological weapons or environmentally destructive processes. However, its application to health-related inventions is nuanced. For instance, biotechnological innovations like genetically modified organisms (GMOs) or certain pharmaceuticals might be scrutinised under this clause if they pose risks to public health or morality (Mgbeoji, 2006). Critics argue that such exclusions could limit incentives for research in vital areas, potentially affecting health outcomes in a country where diseases like malaria and HIV/AIDS remain prevalent (World Health Organization, 2020). Nevertheless, the provision arguably supports the right to health by prioritising safety over commercial gain, reflecting Uganda’s commitment to human rights principles.
The Right to Health in the Ugandan Context
The right to health in Uganda is not explicitly enumerated in the 1995 Constitution but is derived from various provisions and international obligations. National Objective XX mandates the state to ensure access to medical services, while Article 39 affirms the right to a clean and healthy environment, which intersects with health rights (Government of Uganda, 1995). Uganda has also ratified international instruments like the International Covenant on Economic, Social and Cultural Rights (ICESCR), which under Article 12 guarantees the right to the highest attainable standard of health (United Nations, 1966). In domestic jurisprudence, this right has been interpreted broadly; for example, courts have linked it to the right to life under Article 22, emphasising state duties to provide essential services.
However, challenges persist, including limited healthcare infrastructure and high out-of-pocket expenses, exacerbating inequalities (World Health Organization, 2020). Intellectual property laws like the Industrial Property Act play a role here, as patents can influence drug prices and availability. Section 12(b)’s exemption could enhance health rights by blocking patents on inventions that might increase health risks, such as untested medical devices or harmful chemical compounds. Conversely, if applied stringently, it might discourage investment in innovative treatments, thereby indirectly undermining access to health technologies. This duality underscores the need for a balanced interpretation, informed by case law, to ensure the exemption serves rather than hinders public health goals.
Analysis of Section 12(b)’s Impact with Reference to Case Law
To understand Section 12(b)’s impact, it is essential to examine case law, though Ugandan jurisprudence on this specific provision remains limited due to the Act’s relatively recent enactment. Consequently, this discussion draws on relevant international and comparative cases that influence Ugandan law through TRIPS obligations and common law principles. One pivotal case is Novartis AG v Union of India (2013), decided by the Supreme Court of India. Here, the court upheld India’s patent law exclusion of ‘evergreening’—minor modifications to existing drugs to extend patents—under a provision similar to TRIPS Article 27.2, arguing it protected public health by ensuring affordable generics (Supreme Court of India, 2013). In Uganda, where generic medicines are crucial for treating widespread diseases, applying Section 12(b) analogously could prevent patents on marginally improved drugs deemed contrary to public policy, thereby enhancing access to affordable healthcare and supporting the right to health.
Another relevant example is the European Court of Justice’s ruling in Oliver Brüstle v Greenpeace eV (2011), where human embryonic stem cell inventions were deemed non-patentable as contrary to morality under the EU Biotechnology Directive (European Court of Justice, 2011). The court reasoned that commercial exploitation would undermine human dignity, a principle akin to Section 12(b)’s reference to ‘principles of humanity.’ In Uganda, this could impact patents on controversial biotechnologies, such as gene editing for health purposes. If such inventions are excluded, it might protect ethical standards and public health by avoiding risks like unintended genetic mutations. However, it could also limit advancements in treatments for genetic disorders, potentially conflicting with the right to health as interpreted in Ugandan cases like Center for Health, Human Rights and Development (CEHURD) & Ors v Attorney General (2012). In this landmark Ugandan case, the Constitutional Court affirmed state obligations to maternal health services, linking health rights to broader human rights (Constitutional Court of Uganda, 2012). Arguably, Section 12(b) complements this by excluding harmful inventions, but overly broad application might restrict innovations needed to fulfil such obligations.
Furthermore, the case of Harvard College v Commissioner of Patents (2002) in Canada, known as the ‘Oncomouse’ case, rejected patents on higher life forms as contrary to public policy and morality (Supreme Court of Canada, 2002). This resonates with Uganda’s exemption, particularly in agricultural biotechnology affecting food security and health. By preventing patents on genetically modified crops that could harm environmental conservation or health, Section 12(b) indirectly supports nutritional aspects of the right to health. Yet, as Mgbeoji (2006) notes, such exclusions in developing countries like Uganda may deter foreign investment in health innovations, perpetuating dependency on imports.
These cases illustrate that Section 12(b) can positively impact health rights by prioritising safety and ethics, but limited Ugandan case law means interpretations often rely on international precedents. Indeed, without domestic precedents, there is a risk of inconsistent application, potentially weakening health protections.
Conclusion
In summary, Section 12(b) of Uganda’s Industrial Property Act 2014 serves as a vital mechanism to exclude patents on inventions that threaten public health, morality, and related values, thereby aligning with the right to health derived from constitutional and international frameworks. Case law, such as Novartis v India and Brüstle v Greenpeace, demonstrates how similar exemptions enhance access to affordable medicines and uphold ethical standards, potentially benefiting Uganda’s health landscape. However, the provision’s broad scope could hinder innovative health solutions if not carefully balanced, as seen in comparative analyses.
The implications are significant for Uganda, where health challenges demand policies that foster rather than restrict beneficial innovations. Policymakers should consider refining guidelines for Section 12(b) to ensure it supports health rights without stifling progress. Ultimately, while the exemption provides essential safeguards, its true impact depends on judicious interpretation, highlighting the ongoing need for judicial development in this area. This balance is crucial for advancing health equity in a resource-constrained context.
References
- Constitutional Court of Uganda (2012) Center for Health, Human Rights and Development (CEHURD) & Ors v Attorney General, Constitutional Petition No. 16 of 2011.
- European Court of Justice (2011) Oliver Brüstle v Greenpeace eV, Case C-34/10.
- Government of Uganda (1995) The Constitution of the Republic of Uganda.
- Government of Uganda (2014) The Industrial Property Act, 2014. Uganda Legal Information Institute.
- Mgbeoji, I. (2006) Global biopiracy: Patents, plants, and indigenous knowledge. UBC Press.
- Supreme Court of Canada (2002) Harvard College v Commissioner of Patents, [2002] 4 SCR 45.
- Supreme Court of India (2013) Novartis AG v Union of India, Civil Appeal Nos. 2706-2716 of 2013.
- United Nations (1966) International Covenant on Economic, Social and Cultural Rights. Adopted by General Assembly resolution 2200A (XXI).
- World Health Organization (2020) World health statistics 2020: Monitoring health for the SDGs. WHO.
- World Trade Organization (1994) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
